3
Clinical Trials associated with Fecal Microbiota(ProgenaBiome) / Not yet recruitingPhase 1 An Open-Label Phase I Clinical Trial of Vancomycin Followed by Fecal Microbiota Transplant for the Treatment of Parkinson's Disease
FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.
/ Not yet recruitingPhase 1 An Open-Label Phase I Trial of Vancomycin Followed by Familial Fecal Microbiota Transplant in Minor and Adult Subjects With Autism Spectrum Disorder (ASD) for Treatment of Social Deficits and Language Delays.
This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota transplant following a 6-week treatment with Vancomycin in minor and adult subjects with ASD for treatment of social deficits and language delays.
A Single Dose FMT Infusion From a Healthy Family Donor Via Colonoscopy as an Adjunct to Keytruda for the Benefit of Improving Efficacy of Immunotherapy for Metastatic Mesothelioma
The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda
100 Clinical Results associated with Fecal Microbiota(ProgenaBiome)
100 Translational Medicine associated with Fecal Microbiota(ProgenaBiome)
100 Patents (Medical) associated with Fecal Microbiota(ProgenaBiome)
100 Deals associated with Fecal Microbiota(ProgenaBiome)